Latest Biotech News

Bristol Myers Squibb announced that mezigdomide, an oral targeted protein degrader from its CELMoD platform, produced a statistically significant and clinically meaningful improvement in...

Ipsen voluntarily withdrew tazemetostat (Tazverik) from the market and halted ongoing studies after an independent data monitoring committee detected cases of secondary hematologic malignancies in...

Researchers at the Institute of Process Engineering (Chinese Academy of Sciences) introduced a ferritin aggregation cell engager (FACE) that links CAR‑T cells and leukemia cells via CD71,...

A field review mapped the accelerating investment and M&A activity around in‑vivo CAR‑T platforms, which aim to convert off‑the‑shelf delivery into patient T‑cell reprogramming inside the body....

An international research team engineered Saccharomyces boulardii to remove virulence features and demonstrated reduced infection risk in animal models, addressing safety concerns for probiotic...

Verily and Samsung announced a partnership to integrate Galaxy smartwatch data into Verily’s Pre platform, creating an end‑to‑end solution for deploying wearables in clinical trials and analyzing...

Sartorius launched a rationally designed CHO host cell line developed via proteomic profiling and targeted genome editing that delivered up to two‑fold higher expression titers and up to...

Agilent Technologies agreed to acquire Biocare Medical for $950 million in cash to expand its pathology product set, adding immunohistochemistry (IHC), in situ hybridization (ISH/FISH) assays, and...

Researchers reported a CRISPR-based method that reprograms mitochondrial function after myocardial injury, proposing a direct genetic route to restore cardiac energy metabolism. The study details...

Baylor University researchers engineered Listeria monocytogenes to act as a vector that invades colorectal tumors and delivers cytotoxic proteins directly into cancer cells. The study shows the...

Bristol Myers Squibb announced that mezigdomide, an oral protein-degrading CELMoD, met a primary endpoint in a late-stage trial for relapsed or refractory multiple myeloma, showing a statistically...

Xenon Pharmaceuticals reported a positive Phase 3 X-Tole2 study for azetukalner, a KV7 potassium channel opener, with large placebo-adjusted reductions in focal-onset seizure frequency and a...

Ipsen announced a voluntary withdrawal of tazemetostat (Tazverik) after an independent data monitoring committee identified cases of secondary hematologic malignancies in a confirmatory trial in...

Novo Nordisk and Hims & Hers reached an agreement under which Hims will offer Novo’s GLP‑1 medicines at standard telehealth prices and limit promotion of compounded alternatives. Novo agreed to...

Agilent Technologies agreed to acquire Biocare Medical for $950 million in cash to broaden its pathology portfolio with Biocare’s immunohistochemistry, in situ hybridization and FISH assays and a...

Sartorius launched a rationally designed CHO host cell line that the company reported delivers up to two‑fold higher expression titers and up to three‑fold productivity gains across multiple...

Lonza and Genetix Biotherapeutics renewed and expanded their commercial manufacturing agreement to support growing demand for ZYNTEGLO, the FDA‑approved gene therapy for transfusion‑dependent...

The World Health Organization said it will issue recommendations supporting a new class of near‑point‑of‑care molecular TB tests, adoption of tongue‑swab sampling, and pooled sputum testing to...

Roche announced that its oral selective estrogen receptor degrader (SERD) giredestrant failed to meet the primary endpoint in a Phase 3 first‑line breast‑cancer study. The miss contrasts with...

Xenon Pharmaceuticals reported Phase 3 results showing azetukalner produced a 53.2% placebo‑adjusted reduction in focal onset seizure frequency at the 25 mg dose, exceeding prior expectations and...